NASDAQ:TLPH Talphera (TLPH) Stock Price, News & Analysis $1.26 +0.16 (+14.55%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.01 (+0.79%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Talphera Stock (NASDAQ:TLPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Talphera alerts:Sign Up Key Stats Today's Range$1.12▼$1.3550-Day Range$0.39▼$1.1052-Week Range$0.38▼$1.35Volume1.70 million shsAverage Volume937,298 shsMarket Capitalization$57.44 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company Overview Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. Read More Talphera Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreTLPH MarketRank™: Talphera scored higher than 30% of companies evaluated by MarketBeat, and ranked 777th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingTalphera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTalphera has a consensus price target of $5.00, representing about 296.8% upside from its current price of $1.26.Amount of Analyst CoverageTalphera has only been the subject of 1 research reports in the past 90 days.Read more about Talphera's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Talphera are expected to decrease in the coming year, from ($0.64) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Talphera is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Talphera is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTalphera has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Talphera's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.35% of the float of Talphera has been sold short.Short Interest Ratio / Days to CoverTalphera has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Talphera has recently increased by 148.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTalphera does not currently pay a dividend.Dividend GrowthTalphera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.35% of the float of Talphera has been sold short.Short Interest Ratio / Days to CoverTalphera has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Talphera has recently increased by 148.93%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentTalphera has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.Search Interest36 people have searched for TLPH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Talphera to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Talphera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of Talphera is held by insiders.Percentage Held by InstitutionsOnly 37.67% of the stock of Talphera is held by institutions.Read more about Talphera's insider trading history. Receive TLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talphera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLPH Stock News HeadlinesHead to Head Review: Talphera (NASDAQ:TLPH) vs. Prelude Therapeutics (NASDAQ:PRLD)September 29, 2025 | americanbankingnews.comTalphera files to sell 25.04M shares of common stock for holdersSeptember 23, 2025 | msn.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.October 7 at 2:00 AM | Brownstone Research (Ad)CorMedix makes $5M minority equity investment in TalpheraSeptember 9, 2025 | msn.comCorMedix Announces Strategic Minority Investment in TalpheraSeptember 8, 2025 | globenewswire.comTalphera, Inc. Earnings Call Highlights Strategic ProgressAugust 31, 2025 | tipranks.comTalphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trialAugust 27, 2025 | finance.yahoo.comTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal TrialAugust 25, 2025 | prnewswire.comSee More Headlines TLPH Stock Analysis - Frequently Asked Questions How have TLPH shares performed this year? Talphera's stock was trading at $0.5241 at the beginning of the year. Since then, TLPH stock has increased by 140.4% and is now trading at $1.26. How were Talphera's earnings last quarter? Talphera, Inc. (NASDAQ:TLPH) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. Read the conference call transcript. How do I buy shares of Talphera? Shares of TLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Talphera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Talphera investors own include Clearside Biomedical (CLSD), Terran Orbital (LLAP), Adverum Biotechnologies (ADVM), Aptinyx (APTX), Exela Technologies (XELA) and Xeris Biopharma (XERS). Company Calendar Last Earnings8/14/2025Today10/07/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TLPH Previous SymbolNASDAQ:TLPH CIK1427925 Webtalphera.com Phone650-216-3500Fax650-216-6500Employees19Year FoundedN/APrice Target and Rating Average Price Target for Talphera$5.00 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+296.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13 million Net MarginsN/A Pretax Margin-42,140.74% Return on Equity-152.38% Return on Assets-64.32% Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick Ratio2.93 Sales & Book Value Annual Sales$650 thousand Price / Sales88.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book2.68Miscellaneous Outstanding Shares45,590,000Free Float42,988,000Market Cap$57.44 million OptionableOptionable Beta0.03 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TLPH) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.